-
2
-
-
0029931420
-
Toxicology and pharmacology of the chemical warfare agent sulfur mustard
-
J.C. Dacre, and M. Goldman Toxicology and pharmacology of the chemical warfare agent sulfur mustard Pharmacol. Rev. 48 1996 289 326
-
(1996)
Pharmacol. Rev.
, vol.48
, pp. 289-326
-
-
Dacre, J.C.1
Goldman, M.2
-
3
-
-
0000636701
-
The initial clinical trial of nitrogen mustard
-
A. Gilman The initial clinical trial of nitrogen mustard Am. J. Surg. 105 1963 574 578
-
(1963)
Am. J. Surg.
, vol.105
, pp. 574-578
-
-
Gilman, A.1
-
5
-
-
33749073242
-
An anniversary for cancer chemotherapy
-
J. Hirsch An anniversary for cancer chemotherapy JAMA 296 2006 1518 1520
-
(2006)
JAMA
, vol.296
, pp. 1518-1520
-
-
Hirsch, J.1
-
6
-
-
0035720354
-
Origins of cancer therapy
-
R.J. Papac Origins of cancer therapy Yale J. Biol. Med. 74 2001 391
-
(2001)
Yale J. Biol. Med.
, vol.74
, pp. 391
-
-
Papac, R.J.1
-
7
-
-
0021754941
-
Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders
-
L.S. Goodman Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders JAMA 251 1946 2255 2261
-
(1946)
JAMA
, vol.251
, pp. 2255-2261
-
-
Goodman, L.S.1
-
8
-
-
33745216420
-
A concise history of the cancer and leukemia group B
-
R.L. Schilsky A concise history of the cancer and leukemia group B Clin. Cancer Res. 12 2006 3553s 3555s
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 3553s-3555s
-
-
Schilsky, R.L.1
-
9
-
-
33744792098
-
A tribute to Sidney Farber - The father of modern chemotherapy
-
D.R. Miller A tribute to Sidney Farber - the father of modern chemotherapy Br. J. Haematol. 134 2006 20 26
-
(2006)
Br. J. Haematol.
, vol.134
, pp. 20-26
-
-
Miller, D.R.1
-
10
-
-
84869424038
-
The history of leukemia therapy - A personal journey
-
E.J. Freireich The history of leukemia therapy - a personal journey Clin. Lymphoma Myeloma Leuk. 12 2012 386 392
-
(2012)
Clin. Lymphoma Myeloma Leuk.
, vol.12
, pp. 386-392
-
-
Freireich, E.J.1
-
11
-
-
84857515334
-
Off-label use of oncology drugs: The need for more data and then some
-
D.G. Pfister Off-label use of oncology drugs: the need for more data and then some J. Clin. Oncol. 30 2012 584 586
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 584-586
-
-
Pfister, D.G.1
-
12
-
-
34547438878
-
The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy
-
quiz S21-23
-
C. Downs The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy AJHP 64 2007 S13 S15 quiz S21-23
-
(2007)
AJHP
, vol.64
, pp. 13-S15
-
-
Downs, C.1
-
13
-
-
62849098448
-
"off-label" indications for oncology drug use and drug compendia: History and current status
-
M. Soares "Off-label" indications for oncology drug use and drug compendia: history and current status J. Oncol. Pract. 1 2005 102 105
-
(2005)
J. Oncol. Pract.
, vol.1
, pp. 102-105
-
-
Soares, M.1
-
14
-
-
0346657500
-
The growth of patenting and licensing by US universities: An assessment of the effects of the Bayh-Dole act of 1980
-
D.C. Mowery The growth of patenting and licensing by US universities: an assessment of the effects of the Bayh-Dole act of 1980 Res. Policy 30 2001 99 119
-
(2001)
Res. Policy
, vol.30
, pp. 99-119
-
-
Mowery, D.C.1
-
15
-
-
0037032835
-
The protein kinase complement of the human genome
-
G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
-
(2002)
Science
, vol.298
, pp. 1912-1934
-
-
Manning, G.1
-
16
-
-
0025343230
-
Signal transduction by receptors with tyrosine kinase activity
-
A. Ullrich, and J. Schlessinger Signal transduction by receptors with tyrosine kinase activity Cell 61 1990 203 212
-
(1990)
Cell
, vol.61
, pp. 203-212
-
-
Ullrich, A.1
Schlessinger, J.2
-
17
-
-
84908619738
-
An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs
-
M.S. Kinch, and E. Patridge An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs Drug Discov. Today 2014 10.1016/j.drudis.2014.05.012
-
(2014)
Drug Discov. Today
-
-
Kinch, M.S.1
Patridge, E.2
-
18
-
-
70349315347
-
Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
-
E.A. Richey Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J. Clin. Oncol. 27 2009 4398 4405
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4398-4405
-
-
Richey, E.A.1
-
19
-
-
77950937284
-
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
-
O. Wellman-Labadie, and Y. Zhou The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95 2010 216 228
-
(2010)
Health Policy
, vol.95
, pp. 216-228
-
-
Wellman-Labadie, O.1
Zhou, Y.2
-
20
-
-
77953896432
-
Cell signaling by receptor tyrosine kinases
-
M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
-
(2010)
Cell
, vol.141
, pp. 1117-1134
-
-
Lemmon, M.A.1
Schlessinger, J.2
-
21
-
-
61549138378
-
Imatinib and its successors - How modern chemistry has changed drug development
-
B.A. Muller Imatinib and its successors - how modern chemistry has changed drug development Curr. Pharm. Des. 15 2009 120 133
-
(2009)
Curr. Pharm. Des.
, vol.15
, pp. 120-133
-
-
Muller, B.A.1
|